Delivery Order SPE2DX22D0010-SPE2D826FAP44
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on October 6, 2025, for Nucynta ER Tabs 100mg with a ceiling value of $5,338.16. This firm fixed price delivery order, with an ultimate completion date of October 7, 2025, was competitively awarded without set-aside provisions to support the Defense Logistics Agency's Medical Supply Chain. The contract represents a continuation of AmerisourceBergen's...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $12,642.22 for Nucynta Tabs 75mg, a pain management pharmaceutical, by the Defense Logistics Agency's Medical Supply Chain on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 22, 2025, for the supply of Nucynta ER 150 mg tablets (60-count units). This competitively awarded, non-set-aside contract carries a ceiling value of $1,960.50 and is structured as a firm fixed price delivery order with an ultimate completion date of October 23, 2025. The contract represents a fulfillment...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 22, 2025, for Nucynta ER 250 mg tablets (60-count supply). The contract is valued at $1,460.09 with a firm fixed price structure and an ultimate completion date of October 23, 2025. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 8, 2025, for 60 tablets of Nucynta ER 200 mg. This firm fixed-price, competitively awarded contract carries a ceiling value of $2,411.52 and is scheduled for completion by September 9, 2025. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Nucynta ER 50 mg tablets (60-count units) with a contract value of $1,990.55. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through competitive procurement. The contract is set for ultimate completion by September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,288.63 on July 25, 2025, for the supply of Nucynta Tabs 50mg under a firm fixed price contract. This non-set-aside award is funded by the Defense Logistics Agency's Medical Supply Chain and is scheduled for completion by July 28, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Nucynta Tabs 50mg, a pain management pharmaceutical. This firm fixed-price delivery order, valued at $7,938.87, represents a non-competitive set-aside contract and is scheduled for completion by October 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $1,205.75 firm fixed-price delivery order by the Defense Logistics Agency on June 2, 2025, for Nucynta ER 200 mg tablets (60-count supply). The contract, which carries an ultimate completion date of June 3, 2025, represents a non-competitive award and serves the federal medical supply chain supporting military and veteran healthcare systems. This delivery order is issued...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Nucynta ER 50 mg tablets in quantities of 60 units. The contract carries a ceiling value of $1,414.00 and features firm fixed pricing with an ultimate completion date of July 25, 2025. This is a non-set-aside award issued competitively and represents a child contract under AmerisourceBergen's existing...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D826FAP44Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Nucynta Tabs 50mg valued at $4,442.48 under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain on October 23, 2025. The contract is non-competitive, non-set-aside, and represents a single delivery order with an ultimate completion date of October 24, 2025. This award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the contractor to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp serves as a critical federal medical procurement vendor, particularly for Defense Health Agency and military healthcare systems, through its comprehensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's established relationship with DLA demonstrates its capability to meet federal pharmaceutical requirements across multiple therapeutic domains, supporting both routine and specialized medical supply needs for the Department of Defense and related government healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 10/23/25 |